Intraplatelet vascular endothelial growth ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Intraplatelet vascular endothelial growth factor and platelet-derived growth factor: new biomarkers in carcinoembryonic antigen-negative colorectal cancer?
Author(s) :
Chater, Charbel [Auteur]
Université de Lille
Bauters, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Beugnet, Claire [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
M'ba, Lena [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Rogosnitzky, Moshe [Auteur]
Zerbib, Philippe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Université de Lille
Bauters, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Beugnet, Claire [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
M'ba, Lena [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Rogosnitzky, Moshe [Auteur]
Zerbib, Philippe [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Lille Inflammation Research International Center - U 995 [LIRIC]
Journal title :
Gastrointestinal Tumors
Abbreviated title :
Gastrointest. Tumors
Volume number :
5
Pages :
32-37
Publication date :
2018-09
ISSN :
2296-3774
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, ...
Show more >OBJECTIVE: Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, especially in early-stage screening. Intraplatelet angiogenesis regulators (IPAR), such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), have been identified as important regulators of tumor growth in CRC. The aim of this study was to confirm the higher preoperative level of IPAR (VEGF and PDGF) in CRC patients compared to controls and to measure IPAR in CEA-negative CRC patients. METHODS: The data and blood of 30 CRC patients and 30 presumably healthy controls were prospectively analyzed and compared. RESULTS: We confirmed elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients compared to controls. Importantly, IPAR were significantly elevated even in CEA-negative CRC patients. CONCLUSIONS: Elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients suggest new possibilities for postoperative monitoring in CRC patients, especially when CEA is negative.Show less >
Show more >OBJECTIVE: Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, especially in early-stage screening. Intraplatelet angiogenesis regulators (IPAR), such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), have been identified as important regulators of tumor growth in CRC. The aim of this study was to confirm the higher preoperative level of IPAR (VEGF and PDGF) in CRC patients compared to controls and to measure IPAR in CEA-negative CRC patients. METHODS: The data and blood of 30 CRC patients and 30 presumably healthy controls were prospectively analyzed and compared. RESULTS: We confirmed elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients compared to controls. Importantly, IPAR were significantly elevated even in CEA-negative CRC patients. CONCLUSIONS: Elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients suggest new possibilities for postoperative monitoring in CRC patients, especially when CEA is negative.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2024-01-30T10:26:30Z
2024-04-08T12:22:27Z
2024-04-08T12:22:27Z